Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

ESMO Guidelines Committee

doi:10.1016/j.annonc.2020.06.011

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^†

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

592 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1119-1134
Nombre de pages	16
journal	Annals of Oncology
Volume	31
Numéro de publication	9
Les DOIs	https://doi.org/10.1016/j.annonc.2020.06.011
état	Publié - 1 sept. 2020

Accès au document

10.1016/j.annonc.2020.06.011

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{8eb8818b15b042c1a43408d0c66a155c,

title = "Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†",

keywords = "chemotherapy, hormone therapy, prostate cancer, radiotherapy, surgery",

author = "{ESMO Guidelines Committee} and C. Parker and E. Castro and K. Fizazi and A. Heidenreich and P. Ost and G. Procopio and B. Tombal and S. Gillessen",

note = "Funding Information: The ESMO Guidelines Committee would like to thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. CP has reported honoraria from Bayer, Janssen and Advanced Accelerator Applications (AAA) and research grants from Bayer; EC has reported honoraria from Astellas, AstraZeneca, Bayer, Janssen and Pfizer and research grants from AstraZeneca, Bayer and Janssen; KF has reported participation to advisory boards/honoraria for Astellas, AAA, Bayer, Clovis, Curevac, Incyte, Janssen, Merck Sharp & Dohme, Orion, Sanofi; AH has reported paid consultancy for Amgen, Astellas, Ferring, Ipsen, Jansen, Pfizer, Sanofi, Takeda and has received research grants from Astellas and Sanofi; PO has reported institutional honoraria from Janssen, Bayer, Ferring Pharmaceuticals for consultancy and research grants from Merck and Varian; GP has reported advisory boards/honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, Merck Sharp & Dohme, Novartis and Pfizer; BT has reported paid consultancy for Amgen, Bayer, Astellas, Ferring Pharmaceuticals, Janssen, Sanofi-Genzyme, Steba and that he is an investigator for Bayer, Astellas, Ferring Pharmaceuticals, Myovant Sciences, Janssen, Sanofi-Genzyme and Steba; SG has reported advisory role (including independent data monitoring committees) and speakers bureau for AAA International, Active Biotech AB, Amgen, Astellas Pharma, Bayer, Bristol-Myers Squibb, CellSearch, Clovis, CureVac, Dendreon, ESSA Pharma, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxiVAX, Millenium, Nectar, Novartis, Orion, Pfizer, ProteoMediX, Roche, Sanofi, and has reported being the co-inventor for a method for biomarker discovery (on patent application WO 2009138392 A1, granted in China, Europe, Japan and the USA).",

year = "2020",

month = sep,

day = "1",

doi = "10.1016/j.annonc.2020.06.011",

language = "English",

volume = "31",

pages = "1119--1134",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "9",

}

TY - JOUR

T1 - Prostate cancer

T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

AU - ESMO Guidelines Committee

AU - Parker, C.

AU - Castro, E.

AU - Fizazi, K.

AU - Heidenreich, A.

AU - Ost, P.

AU - Procopio, G.

AU - Tombal, B.

AU - Gillessen, S.

N1 - Funding Information: The ESMO Guidelines Committee would like to thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. CP has reported honoraria from Bayer, Janssen and Advanced Accelerator Applications (AAA) and research grants from Bayer; EC has reported honoraria from Astellas, AstraZeneca, Bayer, Janssen and Pfizer and research grants from AstraZeneca, Bayer and Janssen; KF has reported participation to advisory boards/honoraria for Astellas, AAA, Bayer, Clovis, Curevac, Incyte, Janssen, Merck Sharp & Dohme, Orion, Sanofi; AH has reported paid consultancy for Amgen, Astellas, Ferring, Ipsen, Jansen, Pfizer, Sanofi, Takeda and has received research grants from Astellas and Sanofi; PO has reported institutional honoraria from Janssen, Bayer, Ferring Pharmaceuticals for consultancy and research grants from Merck and Varian; GP has reported advisory boards/honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, Merck Sharp & Dohme, Novartis and Pfizer; BT has reported paid consultancy for Amgen, Bayer, Astellas, Ferring Pharmaceuticals, Janssen, Sanofi-Genzyme, Steba and that he is an investigator for Bayer, Astellas, Ferring Pharmaceuticals, Myovant Sciences, Janssen, Sanofi-Genzyme and Steba; SG has reported advisory role (including independent data monitoring committees) and speakers bureau for AAA International, Active Biotech AB, Amgen, Astellas Pharma, Bayer, Bristol-Myers Squibb, CellSearch, Clovis, CureVac, Dendreon, ESSA Pharma, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxiVAX, Millenium, Nectar, Novartis, Orion, Pfizer, ProteoMediX, Roche, Sanofi, and has reported being the co-inventor for a method for biomarker discovery (on patent application WO 2009138392 A1, granted in China, Europe, Japan and the USA).

PY - 2020/9/1

Y1 - 2020/9/1

KW - chemotherapy

KW - hormone therapy

KW - prostate cancer

KW - radiotherapy

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85089363610&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.06.011

DO - 10.1016/j.annonc.2020.06.011

M3 - Article

C2 - 32593798

AN - SCOPUS:85089363610

SN - 0923-7534

VL - 31

SP - 1119

EP - 1134

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

ER -